Abstract
Coronavirus disease (COVID-19) has highlighted both the shortcomings and value of modelling infectious diseases. Infectious disease models can serve as critical tools to predict the development of cases and associated healthcare demand and to determine the set of non-pharmaceutical interventions (NPI) that is most effective in slowing the spread of the infectious agent. Current approaches to estimate NPI effects typically focus on relatively short time periods and either on the number of reported cases, deaths, intensive care occupancy or hospital occupancy as a single indicator of disease transmission. In this work, we propose a Bayesian hierarchical model that integrates multiple outcomes and complementary sources of information in the estimation of the true and unknown number of infections while accounting for time-varying under-reporting and weekday-specific delays in reported cases and deaths, allowing us to estimate the number of infections on a daily basis rather than having to smooth the data. Using information from the entire course of the pandemic, we account for the spread of variants of concern, seasonality and vaccination coverage in the model. We implement a Markov Chain Monte Carlo algorithm to conduct Bayesian inference and estimate the effect of NPIs for 20 European countries. The approach shows good performance on simulated data and produces posterior predictions that show a good fit to reported cases, deaths, hospital and intensive care occupancy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partly funded by a grant by the Volkswagenstiftung.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_confirmed_global.csv https://covid.ourworldindata.org/data/owid-covid-data.csv https://opendata.ecdc.europa.eu/covid19/hospitalicuadmissionrates/csv/data.csv https://api.coronavirus.data.gov.uk/v2/data?areaType=overview&metric=covidOccupiedMVBeds&metric=hospitalCases&format=csv https://raw.githubusercontent.com/OxCGRT/covid-policy-tracker/master/data/OxCGRT_latest.csv https://www.data.gouv.fr/fr/datasets/r/54dd5f8d-1e2e-4ccb-8fb8-eac68245befd https://raw.githubusercontent.com/meganodris/International-COVID-IFR/master/data/population https://github.com/meganodris/International-COVID-IFR/tree/master/data/population
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Links to public data are integrated in the code. All data produced in the study can be replicated with code from https://github.com/RaphaelRe/BayesModelCOVID
